A World-First in Genomics, a Saliva Test to Predict Complications Associated with Type 2 Diabetes, Powered by an Important Public-Private Partnership

January 15, 2024

A new agreement has been signed between OPTITHERA, ELNA Medical Group, and Génome Québec as part of Genome Canada’s Genomic Applications Partnership Program (GAPP). This partnership will ensure the final steps required to bring to market the first-ever genomic test predicting the risk of diabetic complications.

Contact us

Interested in learning more about the

Call us at 514 529-3374

or send us an email at

2815 Sherbrooke Street East, Suite 240
Montreal, Quebec, Canada  H2K 1H2

Alert me as soon as the Optithera test is available.

Abonnement - Anglais